In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
The year in review: Updates and trends
In 2022, we witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues,...